Category Archives: Ulcerative Colitis

PALO ALTO, Calif.--(BUSINESS WIRE)--Endpoint Health, Inc., a Precision-FirstTM therapeutics company, today unveiled its newest precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling. The company will leverage its precision AI platform to identify potential responders to the programs lead asset, EP004, a first-in-class anti-TF monoclonal antibody (mAb), across multiple autoimmune indications. Continue reading →

Mounting concerns over the state of the global economy have pushed stocks to their lowest levels of the year. Accordingly, the S&P 500 index has plunged 23% so far this year.But one sector of the market is holding its own in this downward cycle. Many pharma stocks have squeezed out marginal gains in their share prices in 2022 Continue reading →

If you want to jump on the mushrooms-as-medicine trend, you may consider talking with your doctor or an integrative registered dietician about lions mane. This large, white, shaggy fungus has been part of medicinal culture in East Asia for centuries, used historically as both food and medicine for a variety of health concerns. Continue reading →

Connect Biopharma Holdings Limited Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT,tomorrow, Tuesday, October 4 SAN DIEGO and TAICANG, SUZHOU, China, Oct Continue reading →

After having her large intestine removed, Caitlin Kimpton awaits two more major surgeries to help with her ulcerative colitis. Continue reading →

Nancy Ndure has raised 1,300 for charity as she raises awareness of colitis. (PA Real Life) A woman who hid her 'embarrassing' condition colitis from friends and family for a decade has now refused to stay silent anymore marking her newfound confidence and how far she's come with a skydive. Nancy Ndure, 27, from Telford in Shropshire, has lived with debilitating symptoms and the painful effects of surgeries due to the inflammatory bowel disease she's had since she was a teenager. Continue reading →

Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022 Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance study in moderate-to-severe ulcerative colitis (UC) selected by UEG as "one of the best abstracts" and eligible for an oral presentation at a moderated poster session Principal investigator Prof. Sverine Vermeire, M.D., Ph.D., to present Abivax's poster on October 10, 2022, at 11:54 a.m.- 12:00 (noon) CEST (5:54 a.m.-6:00 a.m. Continue reading →

John Hathaway never imagined itd take this long. But then again, the past eight years have been full of surprises. Continue reading →

Continuing anti-tumor necrosis factor (anti-TNF) therapy after 24 weeks of pregnancy is associated with a lower likelihood of relapse of inflammatory bowel disease (IBD) in pregnant women and fewer premature deliveries, according to a new report. In addition, the numbers of Cesarean sections, stillbirths, serious infections, and small or large weight for gestational size were similar in patients who continued or discontinued anti-TNF treatment after 24 weeks. "Discontinuation of anti-TNF treatment was associated with increased IBD activity and consequently with an increased rate of preterm birth," lead author Antoine Meyer, MD, PhD, a gastroenterologist at Assistance Publique-Hopitaux de Paris, France, and colleagues conclude. Continue reading →

New York, USA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Treg Cell-based Therapies Pipeline Landscape Analysis of 22+ Companies by DelveInsight Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T-cell (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-oncological disease indications. Continue reading →